Socializing a Science-Based Digital Therapeutic for Substance Use Disorders

Last updated: January 2, 2025
Sponsor: Square2 Systems, Inc.
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Stimulant Use Disorder

Opioid Use Disorder

Addictions

Treatment

Behavioral- Group and individual counseling

Laddr® plus Behavioral- Group and individual counseling

Clinical Study ID

NCT05648786
2R44DA047150
2R44DA047150
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the effectiveness of an intervention delivered on a smartphone. This study examines whether this intervention might improve treatment outcomes for people with substance use disorders. The intervention, called Laddr®, is a smartphone application ("app") that provides information and skills that can help people stop using substances. The social version of Laddr® being tested in this study has new features that allow people in treatment for substance use disorders to include a support person in their treatment journey, including a friend, family member, or other acquaintance. This research study will compare the effectiveness of Laddr® in combination with standard outpatient substance use treatment to standard treatment only for substance use disorders.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • In first 30 days of new outpatient treatment episode at the Farnum Center

  • 18 years of age or older

  • Ability to provide informed consent

  • Has access to a functioning smartphone

  • Able to identify a support person who can participate in the study with them

  • Available to participate for the full duration of the study.

Exclusion

Exclusion Criteria:

  • Inability to understand or read English.

Study Design

Total Participants: 189
Treatment Group(s): 2
Primary Treatment: Behavioral- Group and individual counseling
Phase:
Study Start date:
November 09, 2022
Estimated Completion Date:
December 31, 2024

Study Description

Digital therapeutics, or software used to prevent, treat, or manage a medical disorder or disease, are redefining the future of healthcare by providing on-demand access to state-of-the-science care. Digital therapeutics have been developed to treat a wide range of disorders, including substance use disorders (SUD). Developed by the study Principal Investigator (PI) and Co-Investigator (Co-I), Laddr® is a unique mobile platform integrating science-based therapeutic processes to address a wide range of behavioral problems, including SUD.

The current project expands Laddr® to allow users to engage a support network of their choosing in their journey of behavioral change. Individuals can share data from Laddr about their successes and challenges, and their support network can offer anytime/anywhere social support. Social support will be embedded within a strongly science-based digital therapeutic process - thus providing support persons with a clear framework in which to offer support. Research has shown that engaging a support network of non-substance users (e.g., family members, friends) in one's SUD treatment can greatly enhance treatment outcomes - and is aligned with the "community reinforcement" tenet of the CRA treatment model. Interventions that leverage social support networks can help keep individuals engaged in treatment, reinforce their successes, and help them troubleshoot challenges.

This pragmatic, randomized controlled trial aims to evaluate the effectiveness of the social version of Laddr® in improving SUD treatment outcomes. Adults entering outpatient SUD treatment at the Farnum Center in Manchester, New Hampshire (NH) will be offered the opportunity to be randomized to 12 weeks of standard treatment (treatment as usual [TAU] arm), or standard treatment plus the social version of Laddr® (Laddr® arm). The primary study outcome is retention in SUD treatment (time to treatment dropout), and the investigators hypothesize that participants receiving Laddr® will be retained in treatment for a longer duration. Secondary outcomes include participant substance use (self-report and urine toxicology), stages of change, coping skills, recovery capital, and treatment acceptability.

Connect with a study center

  • Farnum Center

    Manchester, New Hampshire 03103
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.